Medium-Hard algorithmic problems
Tech leads face complex coding challenges that test both implementation skills and ability to guide technical decisions under pressure.
0 roles from funded startups and hidden sources. Posted
minutes ago. Updated every 60 seconds
Tech lead interviews balance technical depth with leadership assessment across coding, architecture, and people management.. Explore key insights and preparation tips to help you excel in your interview process.
Tech leads face complex coding challenges that test both implementation skills and ability to guide technical decisions under pressure.
Design large-scale distributed systems while demonstrating technical leadership and decision-making frameworks.
Microservices
Service decomposition strategies
Data Systems
Database scaling and consistency
Infrastructure
Cloud architecture and reliability
Different companies emphasize technical vs people leadership based on their engineering culture and team structure.
Meta
Technical architecture and cross-team collaboration
Stripe
Product engineering leadership and technical mentoring
Compare cost-of-living buying power and how crowded the market is versus other major tech cities—so you can focus your search where the odds fit your goals.
Baltimore offers 65% lower housing costs compared to San Francisco, with median home prices around $200K versus $1.4M in the Bay Area. Tech Leads can afford spacious homes in neighborhoods like Federal Hill or Canton while maintaining strong purchasing power and building wealth faster.
Baltimore's emerging tech scene creates abundant opportunities for experienced Tech Leads without the intense competition of established hubs. Growing cybersecurity and biotech sectors actively recruit senior talent.

New roles go live every minute and the earliest applicants win. Get the freshest, verified listings delivered straight to your inbox before most job seekers ever see them.
👉 Get free daily job postsPearl Diagnostics is a Baltimore-based biotech spun out of Johns Hopkins University in 2014 that builds non-invasive urine-based diagnostic tests for lung infections. Its flagship MycoMEIA Aspergillus urine assay, which received FDA 510(k) clearance in August 2025 and CE approval for the EU, replaces invasive bronchoalveolar lavage procedures used to detect aspergillosis in transplant recipients, cancer patients, and immunocompromised individuals. The company is extending the same antigen-detection platform to other fungal and bacterial pathogens, including a Pseudomonas assay for cystic fibrosis patients.
Raised
$11.2M
Series A · 2026
Key contacts
-
Leadership & hiring contacts indexed
HQ market
Baltimore, Maryland
United States